All In Biotech

Free tool

FAERS Monitor: Xeljanz Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208246 or its brand name (Xeljanz Xr, Tofacitinib Citrate). Reports on generic versions are filed under their own applications.

Reports

184,023

Serious

88,585

48% of reports

Hospitalization

25,552

Death reported

9,502

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective43,969
  • pain26,135
  • arthralgia20,062
  • condition aggravated19,789
  • rheumatoid arthritis19,208
  • fatigue16,945
  • off label use15,236
  • joint swelling14,808
  • headache13,701
  • rash12,289
  • drug intolerance12,020
  • malaise10,773
  • pain in extremity10,467
  • abdominal discomfort10,454
  • nausea10,213

Reports by year received

View as table
YearReports
20081
20091
20112
201230
20131,743
20142,735
20154,604
20169,473
201715,399
201820,836
201922,021
202027,376
202119,223
202224,837
202314,046
202411,500
20258,234
20261,962

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,870,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rheumatoid arthritisSignal19,20823.122.7338,765
drug intoleranceSignal12,02016.115.8149,724
joint swellingSignal14,80815.815.6181,672
condition aggravatedSignal19,7897.97.8112,895
abdominal discomfortSignal10,4547.57.455,946
arthralgiaSignal20,0625.75.776,310
painSignal26,1355.05.083,331
pain in extremitySignal10,4674.24.124,698
drug ineffectiveSignal43,9693.93.998,209
rashSignal12,2893.33.219,400
malaiseSignal10,7732.92.812,914
headacheSignal13,7012.52.512,793
fatigueSignal16,9452.52.515,790
off label useSignal15,2362.02.07,883
nausea10,2131.51.51,636

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.